Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Cagrilintide monotherapy remains investigational, and the CagriSema combination although it has been submitted for regulatory review remained unapproved as of this writing
The market's dominant force is the GLP-1/GIP Receptor Agonist Therapy segment, which accounted for 65.8% of global peptide market value in 2026, growing at 16.43% CAGR by value and 23.95% by volume through 2031
research-only, investigational
Femoral hernias are similar but occur lower in the groin and are more common in women
US$ 27.40
US$ 22.59
US$ 22.11
